Breaking News Instant updates and real-time market news.

ALDX

Aldeyra

$6.80

-0.05 (-0.73%)

08:03
11/29/17
11/29
08:03
11/29/17
08:03

Aldeyra presents noninfectious anterior uveitis Phase 2 clinical trial data

Aldeyra Therapeutics presented new statistical analyses of the results of a randomized, multi-center, investigator-masked, comparator-controlled, parallel-group Phase 2 clinical trial of topical ocular reproxalap (formerly known as ADX-102), a first-in-class aldehyde sequestering agent, to the American Uveitis Society held at the American Academy of Ophthalmology 2017 Annual Meeting. The results of the analyses demonstrated formal statistical non-inferiority (p=0.036 after two weeks of therapy, p=0.048 after four weeks of therapy) of 0.5% reproxalap ophthalmic solution to Pred Forte, a topical ocular corticosteroid, in reducing anterior chamber inflammatory cell count, the standard noninfectious anterior uveitis clinical endpoint. The combination of reproxalap and low-frequency (twice-daily) Pred Forte administration was also statistically non-inferior to Pred Forte monotherapy (four-times-daily). Dr. John Sheppard, an internationally recognized expert in ocular inflammation, gave the presentation, which is available on the investor relations page of the Aldeyra Therapeutics.

ALDX Aldeyra
$6.80

-0.05 (-0.73%)

09/13/17
ADAM
09/13/17
NO CHANGE
Target $27
ADAM
Buy
Aldeyra price target raised to $27 from $12 at Canaccord
Canaccord analyst John Newman raised his price target on Aldeyra to $27 from $12 following the release of positive clinical and statistically significant data in its Phase 2a dry eye study. The analyst believes the data could provide strong support for future approval. Newman maintained his Buy rating on Aldeyra shares.
09/14/17
COWN
09/14/17
NO CHANGE
Target $14
COWN
Outperform
Aldeyra price target raised to $14 from $9 at Cowen
Cowen analyst Ritu Baral raised her price target on Aldeyra to $14 from $9 following the release of "encouraging" topline results from its Phase 2a trial of its dry eye drug, which suggested meaningful clinical benefit. The analyst raised her target based on a new value for the dry eye program. Baral reiterated her Outperform rating on Aldeyra shares.
10/24/17
CANT
10/24/17
INITIATION
Target $22
CANT
Overweight
Aldeyra initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated Aldeyra with an Overweight and $22 price target.
10/25/17
10/25/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with a Buy at HSBC. 2. Albemarle (ALB) initiated with an Outperform at BMO Capital. 3. Norwegian Cruise Line (NCLH) initiated with a Buy at Argus. 4. Uranium Energy (UEC) initiated with a Buy at Roth Capital. 5. Aldeyra (ALDX) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

KOS

Kosmos

$7.84

0.13 (1.69%)

05:29
12/12/17
12/12
05:29
12/12/17
05:29
Hot Stocks
Kosmos completes drilling Lamantin-1 exploration well, offshore Mauritania »

Kosmos Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$51.84

0.75 (1.47%)

05:29
12/12/17
12/12
05:29
12/12/17
05:29
Upgrade
Verizon rating change  »

Verizon upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,168.92

6.92 (0.60%)

05:24
12/12/17
12/12
05:24
12/12/17
05:24
Hot Stocks
AWS, NWCD announce second AWS region in China now available to customers »

Amazon Web Services, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

SAIL

SailPoint Technologies

$14.83

-0.61 (-3.95%)

05:23
12/12/17
12/12
05:23
12/12/17
05:23
Initiation
SailPoint Technologies initiated  »

SailPoint Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTY

Getty Realty

$28.10

0.08 (0.29%)

05:22
12/12/17
12/12
05:22
12/12/17
05:22
Initiation
Getty Realty initiated  »

Getty Realty initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNK

Mallinckrodt

$23.14

0.84 (3.77%)

05:16
12/12/17
12/12
05:16
12/12/17
05:16
Recommendations
Mallinckrodt analyst commentary  »

Mallinckrodt management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

SFIX

Stitch Fix

$23.98

0.38 (1.61%)

05:13
12/12/17
12/12
05:13
12/12/17
05:13
Initiation
Stitch Fix initiated  »

Stitch Fix initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

WEB

Web.com

$23.00

1.2 (5.50%)

05:10
12/12/17
12/12
05:10
12/12/17
05:10
Downgrade
Web.com rating change  »

Web.com downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNPS

Synopsys

$89.56

-0.95 (-1.05%)

05:09
12/12/17
12/12
05:09
12/12/17
05:09
Downgrade
Synopsys rating change  »

Synopsys downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNC

SS&C

$41.38

0.75 (1.85%)

05:09
12/12/17
12/12
05:09
12/12/17
05:09
Downgrade
SS&C rating change  »

SS&C downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOW

ServiceNow

$123.09

1.28 (1.05%)

05:08
12/12/17
12/12
05:08
12/12/17
05:08
Downgrade
ServiceNow rating change  »

ServiceNow downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RNG

RingCentral

$47.55

-0.75 (-1.55%)

05:08
12/12/17
12/12
05:08
12/12/17
05:08
Downgrade
RingCentral rating change  »

RingCentral downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTWO

Q2 Holdings

$40.35

-0.1 (-0.25%)

05:07
12/12/17
12/12
05:07
12/12/17
05:07
Downgrade
Q2 Holdings rating change  »

Q2 Holdings downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

QLYS

Qualys

$59.00

0.55 (0.94%)

05:07
12/12/17
12/12
05:07
12/12/17
05:07
Downgrade
Qualys rating change  »

Qualys downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTC

PTC

$61.44

-0.26 (-0.42%)

05:06
12/12/17
12/12
05:06
12/12/17
05:06
Downgrade
PTC rating change  »

PTC downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEWR

New Relic

$60.00

2.77 (4.84%)

05:06
12/12/17
12/12
05:06
12/12/17
05:06
Downgrade
New Relic rating change  »

New Relic downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

TYPE

Monotype Imaging

$24.40

-0.2 (-0.81%)

05:05
12/12/17
12/12
05:05
12/12/17
05:05
Downgrade
Monotype Imaging rating change  »

Monotype Imaging…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MODN

Model N

$16.00

0.05 (0.31%)

05:05
12/12/17
12/12
05:05
12/12/17
05:05
Downgrade
Model N rating change  »

Model N downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIME

Mimecast

$28.02

-0.72 (-2.51%)

05:04
12/12/17
12/12
05:04
12/12/17
05:04
Downgrade
Mimecast rating change  »

Mimecast downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMPV

Imperva

$41.85

0.3 (0.72%)

05:04
12/12/17
12/12
05:04
12/12/17
05:04
Downgrade
Imperva rating change  »

Imperva downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDDY

GoDaddy

$48.95

0.07 (0.14%)

05:03
12/12/17
12/12
05:03
12/12/17
05:03
Downgrade
GoDaddy rating change  »

GoDaddy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNT

Fortinet

$42.22

0.27 (0.64%)

05:02
12/12/17
12/12
05:02
12/12/17
05:02
Downgrade
Fortinet rating change  »

Fortinet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 17

    Jan

CSGP

CoStar Group

$290.50

-1.84 (-0.63%)

05:02
12/12/17
12/12
05:02
12/12/17
05:02
Downgrade
CoStar Group rating change  »

CoStar Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 15

    Dec

  • 26

    Feb

CHKP

Check Point

$105.85

1.07 (1.02%)

05:01
12/12/17
12/12
05:01
12/12/17
05:01
Downgrade
Check Point rating change  »

Check Point downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

CUDA

Barracuda

$27.61

0.08 (0.29%)

05:00
12/12/17
12/12
05:00
12/12/17
05:00
Downgrade
Barracuda rating change  »

Barracuda downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.